Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a post on LinkedIn about a paper he co-authored with colleagues published in npj Breast Cancer:
“New paper in npj Breast Cancer Nature Portfolio.
We are pleased to share our latest publication validating HER2DX in advanced HER2-positive breast cancer.
Led by Marcin Kubeczko, Fara Brasó Maristany.
This work builds on our previous HER2DX study in the metastatic setting led by Rodrigo Sanchez Bayona (94 patients) and provides a new, independent validation in an additional 122 patients treated in first line with trastuzumab, pertuzumab, and taxane, bringing the total body of evidence to 216 patients.
Importantly, the ERBB2 mRNA score was assessed using exactly the same predefined cutoffs as the current HER2DX assay, ensuring methodological consistency across studies. The prognostic information provided by HER2DX remained independent of standard clinicopathological variables, highlighting its added value beyond routine clinical assessment.
Across cohorts, tumors with high ERBB2 expression showed the most favorable outcomes, supporting the idea that these tumors may be particularly well suited for induction strategies with chemotherapy or ADCs followed by maintenance HP. In contrast, ERBB2-non-high tumors appeared to have poorer outcomes, suggesting that some patients may benefit from upfront ADC-based approaches continued until progression or unacceptable toxicity, along with closer follow-up and alternative sequencing strategies.
Overall, these results reinforce the biological robustness and reproducibility of HER2DX and support the use of genomic profiling to refine prognosis, and potentially treatment sequencing, in the evolving HER2+ metastatic setting.
Grateful to all collaborators, and especially to the patients who made this work possible.”
Title: HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab
Authors: Rodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, Elia Seguí, Esther Carcelero, Pablo Tolosa, Jesús Soberino, Manuel Alva, Tomás Pascual, Laura Lema, Isabel Garcia-Fructuoso, Maria Angeles Cobos-Fernandez, Maria Rey, Luis Manso, Angela Aguirre, Ainhoa Madariaga, Valeria Sirenko, Cristina González-Deza, Paula Blasco, Astrid Mayhua, Oleguer Castillo, Patricia Galván, Esther Sanfeliu, Guillermo Villacampa, Wesley Buckingham, Mercedes Marín-Aguilera, Laia Paré, Patricia Villagrasa, Charles Perou, Julia Maues, Fara Brasó-Maristany, Eva Ciruelos, Aleix Prat
You can read the full article in npj Breast Cancer.
Title: Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane
Authors: Marcin Kubeczko, Sandra Cobo, Rodrigo Sanchez-Bayona, Bartłomiej Pyciński, Jesús Soberino, Ewa Chmielik, Esther Sanfeliu, Maria Rey, Francisco Pardo, Angela Aguirre, Oleguer Castillo, Aleksandra Lesniak, Malgorzata Oczko-Wojciechowska, Esther Carcelero, Barbara Adamo, Maria Vidal, Milana Bergamino, Julia Maues, Guillermo Villacampa, Laia Paré, Patricia Villagrasa, Eva Ciruelos, Aleix Prat, Michal Jarzab, Fara Brasó-Maristany
You can read the full article in NPJ Breast Cancer.
More posts featuring Alex Prat.
